UTHSCSA - Faculty Profiles

Search All | Profile | Publications | Grants | Faculty Index

Velligan, Dawn I PhD

School of Medicine
Psychiatry
(210) 567-5508
velligand@uthscsa.edu

Dr. Velligan is a clinical psychologist who has dedicated her career to the study and treatment of serious mental illness (SMI). Dr. Velligan?s internationally recognized research program focuses on the cognitive deficits associated with schizophrenia, the functional consequences of these deficits, and interventions to decrease cognitive impairment and improve community functioning in individuals with this illness. She has developed Cognitive Adaptation Training a home-based treatment using environmental supports such as signs, checklists, alarms and the organization of belongings to bypass deficits in cognitive functioning and improve adaptive behaviors. CAT has been disseminated to more than 6 countries. An additional research focus is on adherence to oral antipsychotic medications for individuals living in the community. Dr. Velligan recently published an expert consensus guideline on dealing with adherence to medication which has been widely disseminated. She has brought in $4,169,066 in the past fiscal year.

Appointments Education Expertise Publications Grants

1/2010 - Present	Chief, Community Recovery Research and Training (CRRT)	University of Texas Health Science Center San Antonio, Psychiatry, San Antonio, TX
1/2003 - Present	Professor	University of Texas Health Science Center, Psychiatry, San Antonio, TX

Abstract

Soucy MD, Velligan, DI, Martinez, M. Frederick, M.M., Roberts, D.R., Cantu, R., Sierra, C. Innovational Interprofessional Education in Community Psychiatry: A Living Learning Psych Lab San Antonio: Proceedings of The 2nd Annual Faculty Showcase of Educational Innovations, UT Health Science Center; 2015 Oct.

Maples NJ, Velligan DI, Stoner D, Pittman A, Li X, Gold M. Money Follows the Person: Transitioning nursing home residents to independent living; 2013 May. (Schizophrenia Bulletin; vol. 39, no. S1).

Velligan DI, Marder SR, Mintz J, Fredrick M, Dube S, Schooler N. The cross-cultural assessment of functional outcome in schizophrenia; 2013 May. (Schizophrenia Bulletin; vol. 39, no. S1).

Stiekema APM, Quee PJ, Schneider H, van Slogteren S, Wiersma D, Velligan DI, Bruggeman R. A pilot study of cognitive adaptation training as a nursing intervention in schizophrenia inpatients; 2013 May. (Schizophrenia Bulletin; vol. 39, no. S1).

Roberts D, Walss-Bass C, Velligan DI, Carr H. Social cognition, self regulation and neurohormones in schizophrenia; 2013 May. (Schizophrenia Bulletin; vol. 39, no. S1).

Book Chapter

Velligan DI. Factors influencing adherence to treatment plans. In: S. Charles Schulz, Michael F. Green, Katharine J. Nelson. Schizophrenia an Psychotic Spectrum Disorders. New York, NY: Oxford University Press; 2016. p. 247-264.

Velligan DI, Riolo SA, Weston CG. Adherence to medication in psychiatric disorders. In: Allan Tasman, Jerald Kay, Jeffrey A. Lieberman, Michael B. First,Michelle B. Riba. Psychiatry, Fourth edition. 2014.

Editorial

Velligan DI, Kamil SH. Enhancing patient adherence: introducing smart pill devices Ther Deliv 2014 Jun;5(6):611-613.

Electronic/Web Publication

Sajatovic M, Velligan DI. Practical strategies for improving adherence to medication and outcomes 2013 Oct.

Journal Article

Kanzler KE, Robinson PJ, McGeary DD, Mintz J, Potter JS, Munante M, Lopez EJ, Dougherty DM, Hale WJ, Velligan DI. Rationale and design of a pilot study examining Acceptance and Commitment Therapy for persistent pain in an integrated primary care clinic Contemporary Clinical Trials 2018 Mar;66:28-35.

Kidd S, Kerman N, Ernest D, Maples N, Arthur C, de Souza S, Kath J, Herman Y, Virdee G, Collins A, Velligan DI. A Pilot study of a Family Cognitive Adaptation Training Guide for Schizophrenia Psychiatric Rehabilitation Journal 2018 Jan;41:109-117.

Kanzler KE, Robinson P, McGeary DD, Mintz J, Potter JS, Eliot Lopez, Dougherty DM, Hale W, Velligan DI. Rationale and design of a pilot study examining acceptance and commitment therapy for persistent pain in an integrated primary care clinic Contemporary Clinical Trials 2018 Jan;(66):28-35.

Roberts DL, Velligan DI, Fredrick M. The use of access groups for engagement in community mental health post hospitalization Community Mental Health Journal 2018 Jan;54(5):533-539.

Velligan DI, Fredrick MM, Sierra C, Hillner K, Kliewer J, Roberts DL, Mintz J. Engagement-focused care during transitions from inpatient and emergency psychiatric facilities Patient Preference and Adherence 2017 May;11:919-928.

Roberts DL, Liu PY-T, Busanet H, Maples NJ, Velligan DI. A tablet-based intervention to manipulate social cognitive bias in schizophrenia American Journal of Psychiatric Rehabilitation 2017 Apr;20(2):143-155.

Velligan DI, Sajatovic M, Hatch A, Kramata P, Docherty JP. Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness Patient Preference and Adherence 2017 Mar;11:449-468.

Blanchard JJ, Bradshaw KR, Garcia CP, Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Skale TG, Snowden LR, Tandon R, Tek C, Velligan DI, Vinogradov S, O'Gorman C. Examining the reliability and validity of Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study Schizophrenia Research 2017 Jan;.

Dunne PW, Roberts DL, Quinones MP, Velligan DI, Paredes M, Walss-Bass C. Immune markers of social cognitive bias in schizophrenia Schizophrenia Research 2017 Jan;251:319-324.

Allott KA, Killackey E, Sun P, Brewer WJ, Velligan DI. Improving vocational outcomes in first-episode psychosis by adressing cognitive impairments using Cognitive Adaptation Training IOS Press 2017 Jan;56:581-589.

Velligan DI, Roberts D, Martinez M, Fredrick M, Hillner K, Luber P. Following AACP Guidelines for Transitions in Care: The Transitional Care Clinic Psychiatr Serv 2016 Mar;67(3):259-261.

Velligan DI, Brown M. The emerging story of emerging technologies in neuropsychiatry (accepted) Dialogues in Clinical Neuroscience 2016 Feb;.

Brown MA, Bishnoi RJ, Dholakia S, Velligan DI. Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials Expert Rev Clin Pharmacol 2016 Jan;9(4):591-604.

Kidd SA, Virdee G, Mihalakados G, McKinney C, Feingold L, Collins A, Davidson L, Weingarten R, Maples NJ, Velligan DI. The Welcome Basket Revisited: Testing the Feasibility of a Brief Peer Support Intervention to Facilitate Transition from Hospital to Community Psychiatric Rehabilitation Journal 2016 Jan;39:335-342.

Velligan DI, Roberts DL, Sierra C, Fredrick M. What patients with severe mental illness transitioning from hospital to community have to say about care and shared decision making Issues in Mental Health Nursing 2016 Jan;37(6):400-405.

Sarkar S, Hillner K, Velligan DI. Conceptualization and treatment of negative symptoms in schizophrenia World J Psychiatry 2015 Dec;5(4):352-361.

Velligan DI, Mintz J, Sierra C, Martin ML, Fredrick M, Maglinte GA, Corey-Lisle PK. The Daily Activity Report (DAR) a Novel Measure of Functional Outcome for Serious Mental Illness Schizophrenia Bulletin 2015 Dec;.

Nasrallah HA, Harvey PD, Casey D, Csoboth CT, Hudson JI, Julian L, Lentz E, Nuechterlein KH, Perkins DO, Kotowsky N, Skale TG, Snowden R, Tandon R, Tek C, Velligan DI, Vinogradov S, O`Gorman C. The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization Schizophrenia Research 2015 Aug;166(1-3):69-79.

Velligan DI, Roberts DL, Mintz J, Maples NJ, Li X, Medellin E, Brown M. A randomized pilot study of MOtiVation and Enhancement training (MOVE) for negative symptoms in schizophrenia Schizophrenia Research 2015 May;165(2-3):175-180.

Velligan DI, Carroll C, Lage MJ, Fairman K. Outcomes of Medicaid Beneficiaries With Schizophrenia Receiving Clozapine Only or Antipsychotic Combinations Psychiatr Serv 2015 Jan;66(2):127-133.

Stiekema APM, Que PJ, Dethmers M, van den Heuvel ER, Redmeijer JE, Rietberg K, Stant AD, Swart M, van Weeghel J, Aleman A, Velligan DI, Schoevers RA, Bruggeman R, van der Meer L. Effectiveness and cost-effectiveness of cognitive adaptation training as a nursing intervention in long-term residential patients with severe mental illness: Study protocol for a randomized controlled trial Trials 2015 Jan;16(49).

Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ. Self-report measures of medication adherence behavior: Recommendations on optimal use Translational Behavioral Medicine Practice Policy Research 2015 Jan;:1-13.

Weiden PJ, Roma RS, Velligan DI, Alphs L, DiChiara M, Davidson B. The Challenge of Offering Long-Acting Antipsychotic Therapies: A Preliminary Discourse Analysis of Psychiatrist Recommendations for Injectable Therapy to Patients With Schizophrenia J Clin Psychiatry 2015 Jan;76(6):684-690.

Velligan DI, Tai S, Roberts DL, Maples NJ, Brown M, Mintz J, Turkington D. A randomized controlled trial comparing cognitive behavior therapy, cognitive adaptation training, their combination and treatment as usual in chronic schizophrenia Schizophrenia Bulletin 2015 Jan;41(3):597-603.

Allott K, Killackey E, Sun P, Brewer WJ, Velligan DI. The feasibility and acceptability of Cognitive Adaptation Training for first-episode psychosis (in press) Early Intervention in Psychiatry 2014 Nov;.

Velligan DI, Fredrick M, Mintz J, Li X, Rubin M, Dube S, Deshpande SN, Trivedi JK, Gautam S, Avasthi A, Kern RS, Marder SR. The Reliability and Validity of the MATRICS Functional Assessment Battery Schizophrenia Bulletin 2014 Sep;40(5):1047-1052.

Kidd, S., Barbic, Y., Ganguli, S., George, R., Hassan, T., McKenzie, S., Maples NJ, Velligan DI. Testing a modification of cognitive adaptation training: Streamlining the model for broader implementation Schizophrenia Research 2014 Jun;156(1):46-50.

Paredes RM, Quinones MP, Marballi KK, Gao X, Valdez C, Ahuja SS, Velligan DI, Walss-Bass C. Metabolomic Profiling of Schizophrenia Patients at Risk for Metabolic Syndrome International Journal of Neuropsychopharmacology 2014 Feb;17(8):1139-1148.

Velligan DI, Maples NJ, Roberts DL, Medellin E. Integrated psychosocial treatment for negative symptoms American Journal of Psychiatric Rehabilitation 2014 Jan;17:1-19.

Quee PJ, Stiekema A, Wigman J, Schneider H, van der Meer L, Maples NJ, van den Heuvel E, Velligan DI, Bruggeman R. Improving functional outcomes for schizoprenia patients in the Netherlands using cognitive adaptation training as a nursing intervention: A pilot study Schizophrenia Research 2014 Jan;158:120-25.

Dimitrov DH, Lee S, Yantis J, Valdez C, Paredes RM, Braida NN, Velligan DI, Walss-Bass C. Differential Correlations Between Inflammatory Cytokines and Psychopathology in Veterans with Schizophrenia: Potential Role for IL-17 Pathway Schizophrenia Research 2013 Dec;151(1-3):29-35.

Walss-Bass C, Fernandes JM, Roberts DL, Service H, Velligan D. Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia Schizophrenia Research 2013 Jul;147(2-3):387-392.

Arnold JG, Rubin M, Frederick MM, Velligan DI. A qualitative assessment of cross-cultural adaptation of intermediate measures for schizophrenia in multisite international studies Psychiatry Research 2013 Jan;206(2-3):166-172.

Roberts DL, Velligan DI. Can social functioning in schizophrenia be improved through targeted social cognitive intervention? Rehabilitation Research and Practice 2012 Jun;2012.

Federal
Funding Agency	NIH
Title	Cognitive Adaptation Training: Effectiveness in real-world settings and Mechanisms of Action (CAT-EM)
Status	Active
Period	9/2018 - 5/2023
Role	Principal Investigator
Grant Detail	The goal is to test the effectiveness of one year of community treatment (CT) versus Cognitive Adaptation Training (CAT) in 8 community mental health centers across the US. CAT is an in home treatment for people with schizophrenia that uses supports such as signs, checklists, and electronic devices set up in the home or work environment to help people function and work toward recovery. We will assess functional outcome, daily activity and follow through with medication and will examine the way in which CAT is thought to work?by bypassing problems in planning, attention and memory and by creating automatic healthy habits.
Funding Agency	Patient-Centered Outcomes Research Institute (PCORI)
Title	Improving transitional care experience for individuals with serious mental illness
Status	Complete
Period	9/2013 - 8/2016
Role	Principal Investigator
Grant Detail	This grant is designed to investigate patient centered outcomes through comparing the triage group vs. standard intake appointment processes at the Transitional Care Clinic. The clinic serves post-acute psychiatric patients discharged from inpatient units and emergency rooms. The additional treatment component of shared decision making will be offered to participants whom are randomized to the group triage process. Outcomes will be assessed based upon patient satisfaction and attainment of treatment goals.
Private
Funding Agency	Hogg Foundation for Mental Health
Title	Dissemination of the Recovery to Practice Curricula: Psychology
Status	Active
Period	7/2015 - Present
Role	Co-Investigator
Grant Detail	The aim of this project is to disseminate recovery-oriented curriculum content to clinical psychology training and internship programs throughout Texas. The content is designed to improve early career psychologists` knowledge and skill in treating individuals with serious mental illness. I function as the liaison of the program to UTHSCSA`s internship program and to the psychiatry curriculum group`s work with the UTHSCSA psychiatry residency program.
Funding Agency	Boehringer Ingelheim
Title	A phase II randomised, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of orally administered BI 409306 during a 52-week treatment period as an early intervention in patients with attenuated psychosis syndrome
Status	Active
Period	12/2018 - 12/2019
Role	Principal Investigator
Grant Detail	To investigate the efficacy, safety and tolerability of BI 409306 compared to placebo given for 52 weeks to patients with attenuated psychosis syndrome. The study is designed to show superiority of BI 409306 over placebo in preventing first episode of psychosis, as well as improvement in cognition and functional capacity.
Funding Agency	Alkermes
Title	Multi-level fAcilitation of long-acting antipsychotic use (MAP)
Status	Active
Period	1/2018 - 5/2019
Role	Principal Investigator
Grant Detail	This is a demonstration study to develop and test a Multi-level facilitation of long-acting Antipsychotic use/MAP. MAP is a novel behavior change intervention drawn from evidence-based approaches and is designed to improve outcomes and reduce inappropriate use of resources associated with poor adherence. Consistent with a social-cognitive conceptual framework.
Funding Agency	NARSAD
Title	Examining Changes in Inflammatory Markers with Successful Psychosocial Treatment
Status	Active
Period	3/2017 - 3/2019
Role	Principal Investigator
Grant Detail	The main goal is to identify inflammatory markers that improve with successful treatment of negative symptoms in schizophrenia.
Funding Agency	University of Texas Foundation
Title	Military Caregiver Telehealth Initiatives
Status	Complete
Period	5/2017 - 10/2018
Role	Principal Investigator
Grant Detail	This a program providing therapy via evisit to military caregivers unable to leave a disabled veteran at home.
Funding Agency	Genentech
Title	MOSAIC: The Management of Schizophrenia in Clinical Practice: A prospective, non-interventional registry of diverse patients with schizophrenia across the disease spectrum in usual care settings ? course of disease, treatments, and burden of illness
Status	Complete
Period	5/2013 - 5/2018
Role	Principal Investigator
Grant Detail
State
Funding Agency	Texas Department of State Health Services
Title	Money Follows the Person Illness Management & Recovery Program (MFP-IMR)
Status	Active
Period	1/2016 - 12/2019
Role	Co-Investigator
Grant Detail	The goal of the project is to provide an online Psychosocial Rehabilitation (PSR) training using the current Illness Management & Recovery (IMR) curriculum and Cognitive Adaptation Training (CAT) using the CAT curriculum, develop and provide online refresher trainings in both IMR and CAT protocols.
Funding Agency	Center for Medicaid/Medicare Services (CMS)
Title	Transition Care Clinic Interdisciplinary Treatment and Training Program
Status	Complete
Period	9/2013 - 8/2018
Role	Principal Investigator
Grant Detail	The DSRIP is a 1115 Waiver fund through the state from the Center for Medicaid/Medicare Services (CMS). The DSRIP waiver will support the Methodist Health Ministries grant by allowing for more services to be offered at the TCC, while additionally providing training in evidence based practices to the clinicians of the future.
Funding Agency
Title	Daily Activity Report
Status	Complete
Period	10/2015 - 8/2016
Role	Principal Investigator
Grant Detail

Year	Degree	Discipline	Institution
1988	PhD	Clinical Psychology	University of California Los Angeles , CA
1984	MA	Psychology	University of California Los Angeles , CA
1982	BA	Psychology	University of California Los Angeles , CA

Faculty

FAQ

Suggestions

Velligan, Dawn I PhD

Abstract

Book Chapter

Editorial

Electronic/Web Publication

Journal Article

Federal

Private

State